Exelixis, Inc. (FRA:EX9)

Market Cap	9.37B -9.4%
Revenue (ttm)	1.95B +9.9%
Net Income	577.78M +45.2%
EPS	2.03 +53.5%
Shares Out	n/a
PE Ratio	16.22
Forward PE	11.40
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	23
Open	34.80
Previous Close	35.38
Day's Range	34.80 - 34.80
52-Week Range	29.41 - 44.40
Beta	n/a
RSI	41.31
Earnings Date	Jan 13, 2026

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 1,147
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EX9

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial numbers in USD